Bromantane

The following information was compiled in August 2024 and is subject to change as new research is conducted and as new information becomes available:

Description: Bromantane is a novel stimulant described as an actoprotector and psychostimulant with structural similarity to adamantane and memantine.¹ Bromantane was first synthesized for therapeutic use in Russia in the 1980s and has been used as a performance-enhancing drug.² Bromantane was first detected in October 2023 by our laboratory and confirmed in March 2024 after acquiring standard reference material.

Sample Source: Oakland County Medical Examiner (Pontiac, MI)

Sample Appearance: Blood specimen

Pharmacology: Bromantane acts on the GABA receptors to strengthen GABA-inergic mediation and inhibits serotonin and dopamine reuptake.¹

Toxicology: Bromantane has been identified in one toxicology case to date at the CFSRE.

Drug Materials: Bromantane has not been detected in drug materials to date at the CFSRE.

Demographics / Geographics: Toxicology cases originated from Michigan. Bromantane was found alongside novel benzodiazepines (e.g., bromazolam) and traditional stimulants (e.g., methamphetamine).

Legal Status: Bromantane is not currently scheduled in the United States.

Class:

Stimulant

Appearance:

Blood

Formula:

C16H20BrN

MW:

306.2

[M+]:

305

[M+H]+:

306.0852

IUPAC:

N-(4-bromophenyl)adamantan-2-amine

Report Date:

August 20, 2024